Search

Your search keyword '"Chai, Jie"' showing total 461 results
Start Over Author "Chai, Jie"
461 results on '"Chai, Jie"'

64. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy

Author

Xu,Beibei, Lu,Dong, Liu,Kaicai, Lv,Weifu, Xiao,Jingkun, Zhang,Xingming, Zhang,Zhengfeng, Chai,Jie, Wang,Lijun, Xu,Beibei, Lu,Dong, Liu,Kaicai, Lv,Weifu, Xiao,Jingkun, Zhang,Xingming, Zhang,Zhengfeng, Chai,Jie, and Wang,Lijun

Abstract

Beibei Xu,1 Dong Lu,1,2 Kaicai Liu,3 Weifu Lv,2 Jingkun Xiao,2 Xingming Zhang,2 Zhengfeng Zhang,2 Jie Chai,2 Lijun Wang2 1School of Graduate, Bengbu Medical College, Bengbu, 233030, People’s Republic of China; 2Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, People’s Republic of China; 3Infection Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, People’s Republic of ChinaCorrespondence: Dong Lu, Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17, Lujiang Road, Hefei, Anhui, 230001, People’s Republic of China, Tel +86 18056000897, Email hyjh2004@126.comPurpose: Regorafenib is a standard second-line treatment for hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of regorafenib in the treatment of patients with Barcelona clinic liver cancer (BCLC) stage C HCC after failure of the first-line therapy and to analyze factors affecting the efficacy of regorafenib as the second-line treatment.Methods: A retrospective analysis was conducted on 103 BCLC stage C HCC patients who received regorafenib as the second-line treatment. Among them, 51 patients received regorafenib plus transarterial chemoembolization (TACE) and 52 patients received regorafenib alone. Progression-free survival (PFS), overall survival (OS), and adverse events were compared between the two groups, and factors influencing the efficacy of regorafenib were analyzed.Results: In patients with BCLC stage C HCC after failure of the first-line therapy, there was no statistically significant difference in median PFS between regorafenib plus TACE group and regorafenib group (5.3 vs 4.0 months, P=0.432). The median OS was si

Published
2023

68. Supplementary Data from ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer

Author

Li, Zhuqing, primary, Zhou, Wei, primary, Zhang, Yi, primary, Sun, Wei, primary, Yung, Mingo M.H., primary, Sun, Jing, primary, Li, Jing, primary, Chen, Chi-Wei, primary, Li, Zongzhu, primary, Meng, Yunxiao, primary, Chai, Jie, primary, Zhou, Yuan, primary, Liu, Stephanie S., primary, Cheung, Annie N.Y., primary, Ngan, Hextan Y.S., primary, Chan, David W., primary, Zheng, Wei, primary, and Zhu, Wenge, primary

Published
2023
Full Text
View/download PDF

71. PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).

Author

Ding, Xuewei, primary, Wang, Xuejun, additional, Li, Bin, additional, Wang, Longgang, additional, Guo, Honghai, additional, Shang, Liang, additional, Huang, Wenbai, additional, Wu, Liangliang, additional, Ke, Bin, additional, Liu, Yong, additional, Liu, Ning, additional, Wang, Baogui, additional, Cai, Mingzhi, additional, Deng, Jingyu, additional, Zhang, Rupeng, additional, Zhang, Jiancheng, additional, Chai, Jie, additional, Zhao, Qun, additional, Li, Leping, additional, and Liang, Han, additional

Published
2023
Full Text
View/download PDF

82. A Wireless Miniature Device for Neural Stimulating and Recording in Small Animals

Author

Song, Weiguo, Wang, Yongling, Chai, Jie, Li, Qiang, Yuan, Kui, Han, Taizhen, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Jiao, Licheng, editor, Wang, Lipo, editor, Gao, Xinbo, editor, Liu, Jing, editor, and Wu, Feng, editor

Published
2006
Full Text
View/download PDF

93. Abstract P2-13-35: Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial

Author

Wang, Ying, primary, Zhao, Jianli, additional, Yuan, Zhongyu, additional, Zou, Guorong, additional, Li, Haiyan, additional, Ding, Linxiaoxiao, additional, Yang, Yaping, additional, Chai, Jie, additional, Liu, Donggeng, additional, and Yao, Herui, additional

Published
2022
Full Text
View/download PDF

95. Additional file 1 of Comparative study of the effect of preoperative hookwire and methylene blue localization techniques on post-operative hospital stay and complications in thoracoscopic pulmonary nodule surgery

Author

Chu, Senlin, Wei, Ning, Lu, Dong, Chai, Jie, Liu, Shun, and Lv, Weifu

Abstract

Additional file 1. Supplementary Table S1.Multivariable Linear Regression Analysis of the Association Between Age, Nodule Diameter, Nodule Depth, Gender, Patient Position, Nodule Location, Nodule Count, and Localization Technique and the Duration of Surgery (in minutes) Among Our Study Participants. Supplementary Table S2.Multivariable Linear Regression Analysis of the Association Between Age, Nodule Diameter, Nodule Depth, Gender, Patient Position, Nodule Location, Nodule Count, and Localization Technique and the Duration of the Interval Between the End of Localization and the Start of Surgery (in hours) Among Our Study Participants. Supplemental Table S3.Odds Ratios for The Effect of the Localization Technique on the Risk of Hemoptysis.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results